Two frog skin-derived peptides synergistically enhanced polymyxin B's ability to kill resistant bacteria and destroy biofilms without increasing toxicity.
FICI <0.5True synergy achieved when frog-derived Temporin peptides were combined with polymyxin B against resistant bacteria
What the researchers found
Two frog-derived antimicrobial peptides (Temporin-GHaR and Temporin-GHaK) showed synergistic antibacterial activity when combined with the antibiotic polymyxin B against both Pseudomonas aeruginosa and E. coli, achieving a fractional inhibitory concentration index (FICI) below 0.5 — the threshold for true synergy.
The combination worked by synergistically disrupting both outer and inner bacterial membranes, inhibited biofilm formation at lower concentrations than either agent alone, and enhanced destruction of mature E. coli biofilms. Critically, the combination did not increase hemolytic toxicity to mouse red blood cells, suggesting a favorable safety profile.
Why it matters
Antibiotic resistance is a growing global crisis, and Pseudomonas aeruginosa is one of the most dangerous drug-resistant pathogens. Rather than developing entirely new antibiotics — a slow and expensive process — this study shows that pairing existing antibiotics with antimicrobial peptides can restore and enhance their effectiveness, offering a practical combination strategy.
The numbers in context
FICI <0.5 (synergistic) · 2 peptides tested · 2 bacteria targeted · Biofilm inhibition at sub-MIC concentrations · No increased hemolysis
How the study worked
In vitro laboratory study testing Temporin-GHaR and Temporin-GHaK (derived from frog skin antimicrobial peptides) alone and in combination with polymyxin B against P. aeruginosa and E. coli. Methods included checkerboard assays for synergy (FICI), membrane permeability assays (outer and inner membrane disruption), biofilm formation inhibition tests, mature biofilm disruption assays, and hemolysis testing on murine erythrocytes.
Who was studied
Not applicable (in vitro study against P. aeruginosa and E. coli bacterial strains)
What this study cannot tell us
This is entirely in vitro — no animal infection models or clinical data. In vivo pharmacokinetics, peptide stability in biological fluids, and potential for resistance development were not assessed. The peptides' activity against a broader panel of clinical isolates remains unknown.
How to read the evidence
This is an in vitro laboratory study demonstrating synergistic antibacterial activity. While the results are clear and well-characterized with multiple complementary assays, the findings are preclinical and have not been validated in animal models or human infections.
When this study was published
Published in 2026, this reflects the cutting edge of antimicrobial peptide combination therapy research — a field accelerating due to the global antibiotic resistance crisis.
The bigger picture
Antimicrobial peptides represent one of the most promising alternatives to conventional antibiotics. Rather than replacing antibiotics entirely, this study supports the 'adjuvant' approach — using peptides to enhance existing drugs. This strategy could extend the useful lifespan of last-resort antibiotics like polymyxin B while reducing the doses needed, potentially limiting toxicity.
Questions still open
- Would this peptide-antibiotic combination be effective in animal infection models?
- Can the Temporin peptides be produced at scale for clinical development?
- Does the combination slow the development of polymyxin resistance compared to polymyxin alone?
Common questions
What are antimicrobial peptides and where do they come from?
Why combine peptides with existing antibiotics instead of using them alone?
Read the original research
Temporin-GHa-derived peptides enhance the antibacterial and antibiofilm activities of polymyxin B against Pseudomonas aeruginosa and Escherichia coli.
Archives of microbiology, 208(5)
Citation
Zhou, Jinqi; Wang, Yuhuan; Xue, Zhiju; Hu, Fang; Deng, Wenhuan; Tang, Jingxuan; Chen, Yuran; Wang, Rong; Zhang, Yingxia. (2026). Temporin-GHa-derived peptides enhance the antibacterial and antibiofilm activities of polymyxin B against Pseudomonas aeruginosa and Escherichia coli.. Archives of microbiology, 208(5). https://doi.org/10.1007/s00203-026-04798-6